A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

This study is testing a combination of three drugs — golidocitinib (a JAK inhibitor), tislelizumab (an immunotherapy drug), and standard chemotherapy — as a first-line treatment for people with advanced non-small cell lung cancer (NSCLC) whose tumors express a protein called PD-L1. **You may be eligible if...** - You are 18 or older with newly diagnosed, locally advanced, or metastatic NSCLC - Your tumor expresses PD-L1 (at least 1% of tumor cells) - You have not previously received chemotherapy, immunotherapy, or targeted therapy for advanced disease - You have at least one measurable tumor on scans - Your overall health and organ function are adequate **You may NOT be eligible if...** - Your lung cancer has a specific EGFR, ALK, or ROS-1 gene mutation (if you have lung adenocarcinoma) - You have active autoimmune disease or are on immune-suppressing medications - You have previously had a lung transplant or bone marrow transplant - You have active tuberculosis, hepatitis B, hepatitis C, or HIV - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.